160 related articles for article (PubMed ID: 29979855)
1. [In process].
Reisdorf S
Med Monatsschr Pharm; 2017 Jun; 40(6):271-3. PubMed ID: 29979855
[No Abstract] [Full Text] [Related]
2. Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities.
Kaufman TM; Duell PB; Purnell JQ; Wójcik C; Fazio S; Shapiro MD
Circ Res; 2017 Aug; 121(5):499-501. PubMed ID: 28819040
[No Abstract] [Full Text] [Related]
3. JAMA PATIENT PAGE. PCSK9 Inhibitors for Treating High Cholesterol.
Jin J
JAMA; 2015 Dec; 314(21):2320. PubMed ID: 26624842
[No Abstract] [Full Text] [Related]
4. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
Guijarro C; Ruilope LM
Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
[No Abstract] [Full Text] [Related]
5. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.
Stamerra CA; Di Giosia P; Giorgini P; De Feo M; Grassi D; Ferri C; Sahebkar A
J Neurosci Res; 2018 May; 96(5):762-764. PubMed ID: 29152786
[No Abstract] [Full Text] [Related]
7. Economics of lipid lowering with HMG CoA reductase inhibitors.
Illingworth DR
Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
[No Abstract] [Full Text] [Related]
8. PCSK9 inhibitors- A new age in lipid management?
Grant PJ
Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
[No Abstract] [Full Text] [Related]
9. Treatment of Hypercholesterolemia in 2015.
Aronow WS
Am J Ther; 2017; 24(2):e121-e129. PubMed ID: 26422823
[TBL] [Abstract][Full Text] [Related]
10. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
Ioannidis JPA
JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
[No Abstract] [Full Text] [Related]
11. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
[TBL] [Abstract][Full Text] [Related]
12. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
Saußele T
Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
[TBL] [Abstract][Full Text] [Related]
13. The year in cardiology 2015: prevention.
Chapman MJ; Blankenberg S; Landmesser U
Eur Heart J; 2016 Feb; 37(6):510-9. PubMed ID: 26726043
[No Abstract] [Full Text] [Related]
14. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
[No Abstract] [Full Text] [Related]
15. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitors of PCSK9].
Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
[TBL] [Abstract][Full Text] [Related]
17. Proprotein Convertase Subtilisin/Kexin Type 9 Antibody and Statin-Associated Autoimmune Myopathy.
de Dios García-Díaz J; Corral-Bueno IM; Mesa-Latorre JM; Lozano-Durán C; Hernández-Ahijado C
Ann Intern Med; 2019 Jul; 171(1):68-69. PubMed ID: 30776798
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
[TBL] [Abstract][Full Text] [Related]
19. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
Lettino M
G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
[No Abstract] [Full Text] [Related]
20. Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology.
Anguita Sánchez M; Castro Conde A; Cordero Fort A; García-Moll Marimón X; Gómez Doblas JJ; González-Juanatey JR; Lidón Corbi RM; López-Sendón JL; Mostaza Prieto J; Rodríguez Padial L
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1083-1087. PubMed ID: 27650859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
